Overview

Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Primary Objective: To assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and exploratory efficacy of GZ/SAR402671 in enzyme replacement therapy treatment-naïve adult male participants diagnosed with Fabry disease.
Phase:
Phase 2
Details
Lead Sponsor:
Genzyme, a Sanofi Company